INVO Bioscience enters exclusive distribution agreement with Ming Mei Technology for Taiwan

INVO Fertility, Inc.

Exclusive distributor for Taiwan with initial 1-year term, renewable automatically.
Ming Mei estimates ~90% coverage of reagents and consumables in Taiwan's reproductive medicine market.
Planned introduction of INVOcell in early 2023; Taiwan had ~55,000 ART cases in 2019.
CEO cites decreasing birth rates and rising treatment costs as market drivers.
Agreement includes exclusive rights to INVO trademarks in Taiwan for product sales.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

INVO Fertility, Inc. entered into Distribution Agreement with Ming Mei Technology Co. Ltd (effective 2023-01-03).

Action: entry
Agreement: supply
Counterparty: Ming Mei Technology Co. Ltd
Effective: 2023-01-03

Exact text from the filing

On January 3, 2023, we entered into a Distribution Agreement with Ming Mei Technology Co. Ltd (“Distributor”) to distribute the INVOcell system to Taiwan (ROC) under which Distributor was appointed as the exclusive distributor in Taiwan (ROC).

View on SEC.gov

249 material agreements filed in the last 30 days. Browse all material agreements →

INVO Fertility, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-000622

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.